United Therapeutics Corporation (UTHR)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	2,268,200	2,147,800	2,060,800	1,939,800	1,903,900	1,743,300	1,676,600	1,657,700	1,666,900	1,751,900	1,687,000	1,601,600	1,491,500	1,399,000	1,425,300	1,442,500	1,448,800	1,519,100	1,530,300	1,601,200
Receivables	US$ in thousands	278,900	258,600	272,700	134,500	220,400	231,700	173,400	170,500	198,700	212,800	173,400	141,100	157,400	152,300	172,000	149,600	151,400	183,600	181,000	159,800
Receivables turnover		8.13	8.31	7.56	14.42	8.64	7.52	9.67	9.72	8.39	8.23	9.73	11.35	9.48	9.19	8.29	9.64	9.57	8.27	8.45	10.02

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $2,268,200K ÷ $278,900K
= 8.13

United Therapeutics Corp's receivables turnover has shown variability in the past eight quarters. The ratio ranged from a low of 7.74 in Q2 2023 to a high of 14.73 in Q1 2023. Generally, a higher turnover ratio indicates that the company efficiently collects its accounts receivable within a shorter period. In contrast, a lower ratio suggests a longer collection period, which could potentially lead to liquidity issues or an inefficient credit policy.

The declining trend in receivables turnover from Q1 2023 to Q2 2023 may indicate a slowdown in the collection of receivables during this period. However, the subsequent increase in Q3 and Q4 2023 could suggest an improvement in the efficiency of the company's accounts receivable collection process.

Overall, it would be essential for the company to closely monitor its receivables turnover ratio to ensure timely collection of outstanding debts and maintain healthy liquidity levels.